tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer - PubMed
4 days ago
- #tRF-1432
- #Chemoresistance
- #Breast cancer
- tRF-1432 is upregulated in chemoresistant breast cancer tissues and cell lines.
- tRF-1432 enhances resistance to adriamycin by promoting tumor cell survival and suppressing apoptosis.
- tRF-1432 interacts with RBMS1, attenuating its destabilization of IMPDH2 mRNA, leading to increased IMPDH2 expression.
- Increased IMPDH2 expression enhances purine metabolic reprogramming, elevating GTP levels and sustaining survival signaling.
- Pharmacological inhibition of IMPDH2 with mycophenolic acid (MPA) reverses chemoresistance in vitro and in vivo.
- The tRF-1432/RBMS1/IMPDH2 axis is a potential therapeutic target for overcoming breast cancer chemoresistance.